Last reviewed · How we verify
NCT06285370
A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy
Phase 4 trial testing Mogamulizumab in Cutaneous T-Cell Lymphoma in 23 participants. Participants enrolled and being followed up; not accepting new ones.
12 August 2025
Quick facts
| Lead sponsor | Kyowa Kirin China Pharmaceutical Co., Ltd. |
|---|---|
| Phase | Phase 4 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 23 |
| Start date | 29 May 2023 |
| Primary completion | 12 August 2025 |
| Estimated completion | 13 November 2025 |
| Sites | 8 locations across China |
Drugs / interventions tested
- Mogamulizumab (MOGAMULIZUMAB) — full drug profile →
Conditions studied
- Cutaneous T-Cell Lymphoma — all drugs for Cutaneous T-Cell Lymphoma →
Sponsor
Kyowa Kirin China Pharmaceutical Co., Ltd.
Who can join
18 and older, any sex, with Cutaneous T-Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of the study is to evaluate the efficacy and safety of mogamulizumab (KW-0761) in chinese subjects with mycosis fungoides or sézary syndrome previously treated with systemic therapy
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06285370
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Mogamulizumab
Trials testing the same drug.
- NCT07529405 — A Study of VG712 in Patients With Mycosis Fungoides · Phase 2 · not yet recruiting
- NCT06698003 — A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1 · Phase 2 · recruiting
- NCT05414500 — Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides · Phase 1 · recruiting
- NCT04930653 — Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma · Phase 2 · recruiting
- NCT04848064 — Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphoma · Phase 1 · recruiting
Other recruiting trials for Cutaneous T-Cell Lymphoma
Currently open trials in the same condition.
- NCT07055477 — A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T- · Phase 1 · recruiting
- NCT06698822 — A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTC · Phase 2 · recruiting
- NCT06382844 — Novel Flow-cytometry Approaches to Improve the Detection of Tumor Cells in CTCL · recruiting
Other Kyowa Kirin China Pharmaceutical Co., Ltd. trials
Trials by the same sponsor.
- NCT03123406 — Efficacy and Safety of Cinacalcet in Ca, P and iPTH Levels in Patients With Mild, Moderate and Severe SHPT · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06285370 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kyowa Kirin China Pharmaceutical Co., Ltd.
- Last refreshed: 18 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06285370.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing